EASL in Medical News

Human Genome Sciences Announces Second-Quarter 2009 Financial Results and Key Developments

...ry Authorities Completed - on Track for Fall Submission of Global Marketing Applications; Positive Phase 3 Results in Chronic Hepatitis C Presented at easl HGS and Novartis have selected ZALBIN as the brand name for albinterferon-alfa 2b (formerly Albuferon) in the United States. Joulferon(R) h...

The European Association for the Study of the Liver renews publishing partnership with Elsevier

...lls for Elsevier to publish the society's flagship journal, the Journal of Hepatology ( http://www.jhep-elsevier.com/ ), for the next five years. easl is a society with over 1500 members. The society has given rise to a significant number of international clinical trials and research collaborations i...

GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus

... blood borne pathogens during sports: risk and prevention. Ann Int Med 1995; 122 (4): 283 8.   De Franchis et al Consensus statement, easl International Consensus Conference on Hepatitis B J Hepatol 2003; 39: S3-S25 9.   Zuckerman JN., Steffen R. J Travel Med (2000): 7;...

Future for radioembolisation in patients with advanced hepatocellular carcinoma

...ss microspheres is a safe and effective treatment for patients with advanced HCC portal vein thrombosis, according to new research presented today at easl 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark. According to the researchers, these finding...

HIV positive and HIV negative patients have similar survival rates following liver transplant

...April: HIV positive and HIV negative patients have comparable survival rates following liver transplant, according to new research presented today at easl 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark. The study results showed no difference in survi...

New oncogene gives valuable insight into hepatocellular tumors in humans

... Copenhagen, Denmark, Thursday 23 April: The first identification of GP130 somatic activating mutations* in human tumours was announced today at easl 2009, the Annual Meeting of the European Association for the Study of Liver Disease in Copenhagen, Denmark. Identification of recurrent somatic mut...

Liver disease responsible for most alcohol-related illness and deaths

...revalent cause of alcohol-related deaths, followed by car accidents and cancer, according to new research conducted in Portugal and presented today at easl 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark. The study also showed that alcohol-related disease...

First evidence for DNA-based vaccination against chronic hepatitis C

...gen, Denmark, Thursday 23 April: The first-proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C was announced today at easl 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark. In the first clinical trial of a therapeuti...

Diabetes, obesity and hypertension increase mortality in hepatitis C patients

...The specific impact of metabolic syndrome on mortality in hepatitis C patients has been revealed by new research to be presented on Sunday April 26 at easl 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark. According to the results of the research, t...

International Liver Congress 2009

...in Copenhagen, Denmark. Press registration is free of charge for all holders of a valid press card / formal journalist credentials. The official easl press conference will be held from 13.15 to 14.15 CET on Wednesday 22nd April. This will be preceded by a finger buffet for press and speakers from 1...

Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights

...ubmit an abstract to the European Association for the Study of the Liver (EASL) to present antiviral and safety data from all three dose levels at the easl Annual Meeting in late April. 14-day Healthy Volunteer Study . In order to extend the pharmacokinetic and safety profile of ANA598, Anadys ha...